CommercialPrior AuthHigh impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology, Neurology +2 more·Medical Policy
Effective date
Sep 17, 2026
We identified it
Jul 8, 2026
Summary
Arkansas Blue Cross updated coverage criteria for five specialty medications (Duopa, Adstiladrin, Imaavy, Vyvgart, Vyvgart Hytrulo) and restructured white blood cell growth factor coverage with new preferred/non-preferred product lists and clinical criteria for febrile neutropenia prophylaxis. Key changes include removal of acetylcholine receptor positivity requirements for efgartigimod products, addition of off-label bladder cancer criteria for nadofaragene firadenovec-vncg, and comprehensive updates to WBC growth factor authorization rules based on chemotherapy risk stratification.
Action Required
By September 17, 2026: Billing team must implement the following changes: (1) Update billing system to reflect new preferred/non-preferred WBC growth factor product hierarchy—flag Q5108, J2506, Q5110, Q5101 as preferred agents; flag Q5130, J1447, J2820, J1442, Q5148, Q5122, Q5125, J1449, J9361, Q5127, Q5111, Q5120, and Q5169/J3590 (when active) as non-preferred products requiring prior authorization. (2) For oncology claims, implement new clinical criteria requiring documentation of: chemotherapy regimen name, febrile neutropenia risk category (high ≥20%, intermediate ≥10%), treatment intent (curative/survival prolongation/symptom management), and applicable risk factors from the Carelon MBM Appropriate Use Criteria guidelines. (3) For Adstiladrin (Policy 2023020) claims, verify diagnosis of high-risk non-muscle invasive bladder cancer with specified tumor staging and ECOG performance status 0-2. (4) For efgartigimod/Vyvgart products, remove requirement for acetylcholine receptor positivity testing in prior authorization workflows. (5) For Duopa claims, ensure documentation that vitamin B6 levels were evaluated prior to initiation and periodically during treatment. (6) Providers must update authorization request forms to collect new clinical documentation requirements. (7) Billing software must prevent billing of multiple WBC growth factor agents in a single chemotherapy cycle. Failure to implement will result in claim denials for non-compliance with coverage criteria.